Regeneron Pharmaceuticals, Inc.
REGN · Nasdaq
REGN · Nasdaq
Regeneron is a biopharmaceutical company that develops and sells prescription medicines. Its commercial portfolio includes Dupixent, Eylea HD, legacy Eylea and Libtayo, with the latest quarter showing particular strength in Dupixent, Eylea HD and Libtayo. The company makes money primarily through pharmaceutical product sales, but the supplied evidence does not provide segment reporting, product-by-product contributions or customer-channel detail. Regeneron reports $14.3 billion of fiscal 2025 revenue and $4.5 billion of net income, compared with $14.2 billion and $4.4 billion, respectively, in fiscal 2024.
Regeneron rose 9.42%, from $695.18 to $760.66, with nearly all of the advance concentrated in the 6.2% gain on July 30 and the 3.3% rise on July 31. The main catalyst was its second-quarter earnings report: revenue grew 17% year over year to $4.3 billion, beating expectations as Dupixent, Eylea HD and Libtayo performed strongly. Robust Eylea HD demand and higher Dupixent profits offset declining legacy Eylea sales, supporting the sharp repricing. The stock then consolidated, slipping 0.4% on August 3 before adding 0.2% on August 4. There was no material reversal after the earnings-driven jump, although broader biotechnology ETF outflows were a conflicting market signal.
New FDA Drug Approvals - August 2026
